Berberine inhibits the expression of TNFα, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARγ pathway

Chen, F. L.; Yang, Zixiao; Liu, Y.; Li, L. X.; Li, Weimin; Wang, X. C.; Zhou, Wen‐Jie; Yang, Yehong; Hu, Renming

doi:10.1007/s12020-008-9089-3

Cited by 76 publications

(46 citation statements)

References 35 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on this viewpoint, the prevention of Ang II signaling by AT1R blockers (ARBs) has been extensively used in diabetic patients (1,2). Among them, irbesartan, a so-called metabosartan, is a unique ARB with the ability to increase the transcriptional activity of PPAR-γ, which was found to decrease pro-inflammatory cytokines in monocytes (4) and prevent up-regulation of MCP-1 receptor expression in animal studies (5). Since irbesartan stimulated PPAR-γ activity in an AT1R-deficient cell model, the stimulatory effect of irbesartan on PPAR-γ activity is independent of its AT1R blockade (6).…”

Section: Introductionmentioning

confidence: 99%

Irbesartan improves endothelial dysfunction, abnormal lipid profile, proteinuria and liver dysfunction in Zucker diabetic fatty rats independent of glucose and insulin levels

Shimamura

Nakagami

Shimosato³

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Treatment with angiotensin type 1 receptor blockers (ARBs) is known to improve renal dysfunction and glucose metabolism in obese diabetic animal models and humans. This study examined the effects of irbesartan, a unique ARB with PPARγ activation, on endothelial dysfunction, renal dysfunction, abnormal lipid profile, and liver dysfunction in obese fa/fa Zucker diabetic fatty (ZDF) rats. ZDF rats were administered irbesartan (30 mg/kg/day p.o.) for 12 weeks. Blood pressure, glucose metabolism, lipid profile and renal function were measured every 4 weeks. Response of mesenteric artery rings to acetylcholine was also evaluated as an index of endothelial function after 12 weeks of treatment. Although irbesartan did not affect glucose and insulin levels in both glucose and insulin tolerance tests, decreases in systolic blood pressure, dyslipidemia, and urinary protein excretion were noted from 4 weeks after the start of treatment and continued until 12 weeks. Endothelial and liver dysfunctions were also improved after 12 weeks of treatment. Compared to previous reports showing the effects of irbesartan at later time points such as 6 or 12 months, the present study demonstrated that a low-dose of irbesartan had favorable effects from the early period of treatment, independent of glucose metabolism. Our findings suggest that a low-dose of irbesartan improves diabetic complications quickly after starting treatment, and may support the use of irbesartan for preventing progression of diabetic complications. IntroductionDiabetic angiopathy, nephropathy, and dyslipidemia are important risk factors for multiple organ dysfunctions such as ischemic heart disease and chronic renal failure. There is growing evidence that angiotensin (Ang) II plays a key role in the activation of inflammation and oxidative stress, which accelerate the progression of such diseases through the Ang II type 1 receptor (AT1R) (1-3). Based on this viewpoint, the prevention of Ang II signaling by AT1R blockers (ARBs) has been extensively used in diabetic patients (1,2). Among them, irbesartan, a so-called metabosartan, is a unique ARB with the ability to increase the transcriptional activity of PPAR-γ, which was found to decrease pro-inflammatory cytokines in monocytes (4) and prevent up-regulation of MCP-1 receptor expression in animal studies (5). Since irbesartan stimulated PPAR-γ activity in an AT1R-deficient cell model, the stimulatory effect of irbesartan on PPAR-γ activity is independent of its AT1R blockade (6). Importantly, two large prospective, randomized, double-blind clinical trials demonstrated that irbesartan prevented the onset (7) and progression of chronic kidney disease (8), independent of its blood pressure-lowering effect. Additionally, endothelial dysfunction was significantly improved by short-term atorvastatin and/or irbesartan in type 2 diabetic patients without affecting blood pressure (2). These data suggest that irbesartan could have organ-protective actions independent of blood pressure lowering, possibly due to PPA...

show abstract

Section: Introductionmentioning

confidence: 99%

Irbesartan improves endothelial dysfunction, abnormal lipid profile, proteinuria and liver dysfunction in Zucker diabetic fatty rats independent of glucose and insulin levels

Shimamura

Nakagami

Shimosato³

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Berberine is well known for its anti-inflammatory capacity and can inhibit the expression of proinflammatory cytokines 42,43 through inhibiting the nuclear factor-kappa B (NF-jB) pathway. 44,45 Considerable evidence has accumulated to emphasize the importance of inflammatory processes in the etiology of diabetic complications, including diabetic neuropathy.…”

mentioning

confidence: 99%

Berberine Ameliorates Cold and Mechanical Allodynia in a Rat Model of Diabetic Neuropathy

Kim

2013

Journal of Medicinal Food

View full text Add to dashboard Cite

This study evaluated the antiallodynic properties of berberine on cold and mechanical allodynia after streptozotocin (STZ)-induced diabetes using a rat model. Diabetic neuropathy was induced in rats by intraperitoneal injection of STZ. To measure cold and mechanical allodynia, a 4°C plate and von Frey filament were used, respectively. Cold and mechanical allodynia induced by diabetes were significantly decreased by single and repeated intraperitoneal treatment of amitriptyline at 10 mg/kg, and berberine at 10 and 20 mg/kg. The hepatic malondialdehyde, superoxide dismutase, catalase, and glutathione peroxidase activities were significantly increased in diabetic rats as compared with those in intact rats; however, in amitriptyline-and berberine-treated rats, they were significantly decreased as compared to the STZ control. The overall effects of berberine 20 mg/kg on cold and mechanical allodynia were quite similar to those of amitriptyline 10 mg/kg, and berberine exhibited similar antioxidant effects as the same dosage of amitriptyline. In conclusion, berberine (10 and 20 mg/kg) was observed to have antiallodynic effects against diabetes, which are presumed to be associated with antioxidative effects. It can be considered that the anti-inflammatory or antidepressant capacity of berberine could contribute to the antiallonynic effects shown in this study.

show abstract

“…Plusieurs travaux ont noté plutôt des effets immunostimulants [2,6,32], apoptotiques [9,11,19,22] et anticancéreux [8,12,24,25,30,39] de la berberine. Cependant, aucun travail ne s'est intéressé à évaluer l'effet suppresseur des composés de l'extrait aqueux et celui de la fraction protéique de Berberis hispanica sur le pourcentage des sous-populations leucocytaires.…”

Section: Discussionunclassified

Antidepressive, antinociceptive and immunomodulatory effects of aqueous and proteic extracts of Berberishispanica Boiss. & Reut. from Morocco

et al. 2011

View full text Add to dashboard Cite

Berberine inhibits the expression of TNFα, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARγ pathway

Cited by 76 publications

References 35 publications

Irbesartan improves endothelial dysfunction, abnormal lipid profile, proteinuria and liver dysfunction in Zucker diabetic fatty rats independent of glucose and insulin levels

Irbesartan improves endothelial dysfunction, abnormal lipid profile, proteinuria and liver dysfunction in Zucker diabetic fatty rats independent of glucose and insulin levels

Berberine Ameliorates Cold and Mechanical Allodynia in a Rat Model of Diabetic Neuropathy

Antidepressive, antinociceptive and immunomodulatory effects of aqueous and proteic extracts of Berberishispanica Boiss. & Reut. from Morocco

Contact Info

Product

Resources

About